In 2019, Crizanlizumab, a P-selectin inhibitor, was approved by the FDA for the prevention of vaso-occlusive crises in patients with sickle cell disease (Figure 1)
Transepithelial resistance measurements Caco-2 cells were seeded onto 12 mm polycarbonate membrane inserts (PCF membrane inserts, Millipore, Germany) and bathed in DMEM/F12 medium which contained phenol red, 10% FBS, penicillin (100 units/ml) and streptomycin (10 g/ml)
Resistance training preserves muscle mass and metabolic rate
Custom Protocol Design Based on your consultation, we design a personalized BPC- 157 protocol
doi: 10.1007/s00441-008-0658-9 24
It demonstrated increased efficiency of oxidative phosphorylation in rat mitochondria in vitro and possible antioxidant effects are also attributed to it